Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Metabolomics reveals tepotinib-related mitochondrial dysfunction in MET-activating mutations-driven models.

Poliaková M, Felser A, Pierzchala K, Nuoffer JM, Aebersold DM, Zimmer Y, Zamboni N, Medová M.

FEBS J. 2019 Apr 16. doi: 10.1111/febs.14852. [Epub ahead of print]

PMID:
30993872
2.

Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase.

Orlando E, Aebersold DM, Medová M, Zimmer Y.

Cancer Lett. 2019 Feb 28;443:189-202. doi: 10.1016/j.canlet.2018.12.001. Epub 2018 Dec 11.

PMID:
30550851
3.

Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease.

Nisa L, Barras D, Medová M, Aebersold DM, Medo M, Poliaková M, Koch J, Bojaxhiu B, Eliçin O, Dettmer MS, Angelino P, Giger R, Borner U, Caversaccio MD, Carey TE, Ho L, McKee TA, Delorenzi M, Zimmer Y.

Mol Cancer Res. 2018 Dec;16(12):1912-1926. doi: 10.1158/1541-7786.MCR-18-0056. Epub 2018 Aug 14.

PMID:
30108165
4.

Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia.

Glück AA, Orlando E, Leiser D, Poliaková M, Nisa L, Quintin A, Gavini J, Stroka DM, Berezowska S, Bubendorf L, Blaukat A, Aebersold DM, Medová M, Zimmer Y.

Oncogene. 2018 Jul;37(30):4181-4196. doi: 10.1038/s41388-018-0256-6. Epub 2018 May 2.

PMID:
29717265
5.

OMIP-045: Characterizing human head and neck tumors and cancer cell lines with mass cytometry.

Brodie TM, Tosevski V, Medová M.

Cytometry A. 2018 Apr;93(4):406-410. doi: 10.1002/cyto.a.23336. Epub 2018 Apr 12. No abstract available.

6.

The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer.

Poliaková M, Aebersold DM, Zimmer Y, Medová M.

Mol Cancer. 2018 Feb 19;17(1):27. doi: 10.1186/s12943-018-0798-9. Review.

7.

PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.

Nisa L, Häfliger P, Poliaková M, Giger R, Francica P, Aebersold DM, Charles RP, Zimmer Y, Medová M.

Mol Cancer. 2017 May 22;16(1):93. doi: 10.1186/s12943-017-0660-5.

8.

Hepatocyte growth factor secreted by bone marrow stem cell reduce ER stress and improves repair in alveolar epithelial II cells.

Nita I, Hostettler K, Tamo L, Medová M, Bombaci G, Zhong J, Allam R, Zimmer Y, Roth M, Geiser T, Gazdhar A.

Sci Rep. 2017 Feb 3;7:41901. doi: 10.1038/srep41901.

9.

Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer.

Francica P, Nisa L, Aebersold DM, Langer R, Bladt F, Blaukat A, Stroka D, Martínez MR, Zimmer Y, Medová M.

Clin Cancer Res. 2016 Nov 1;22(21):5322-5336. Epub 2016 May 16.

10.

Senescence as biologic endpoint following pharmacological targeting of receptor tyrosine kinases in cancer.

Francica P, Aebersold DM, Medová M.

Biochem Pharmacol. 2017 Feb 15;126:1-12. doi: 10.1016/j.bcp.2016.08.022. Epub 2016 Aug 27. Review.

PMID:
27574725
11.

Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer.

Piguet AC, Medová M, Keogh A, Glück AA, Aebersold DM, Dufour JF, Zimmer Y.

Genes Cancer. 2015 Jul;6(7-8):317-327.

12.

Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation.

Mikami K, Medová M, Nisa L, Francica P, Glück AA, Tschan MP, Blaukat A, Bladt F, Aebersold DM, Zimmer Y.

Mol Cancer Res. 2015 Dec;13(12):1544-53. doi: 10.1158/1541-7786.MCR-15-0022. Epub 2015 Sep 10.

13.

KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells.

Leiser D, Medová M, Mikami K, Nisa L, Stroka D, Blaukat A, Bladt F, Aebersold DM, Zimmer Y.

Mol Oncol. 2015 Aug;9(7):1434-46. doi: 10.1016/j.molonc.2015.04.001. Epub 2015 Apr 14.

14.

Profiling invasiveness in head and neck cancer: recent contributions of genomic and transcriptomic approaches.

Nisa L, Aebersold DM, Giger R, Caversaccio MD, Borner U, Medová M, Zimmer Y.

Cancers (Basel). 2015 Mar 31;7(2):585-97. doi: 10.3390/cancers7020585. Review.

15.

Interplay between receptor tyrosine kinases and hypoxia signaling in cancer.

Glück AA, Aebersold DM, Zimmer Y, Medová M.

Int J Biochem Cell Biol. 2015 May;62:101-14. doi: 10.1016/j.biocel.2015.02.018. Epub 2015 Mar 6. Review.

PMID:
25747905
16.

Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer.

Nisa L, Aebersold DM, Giger R, Zimmer Y, Medová M.

Pharmacol Ther. 2014 Sep;143(3):337-49. doi: 10.1016/j.pharmthera.2014.04.005. Epub 2014 Apr 27. Review.

PMID:
24786972
17.

Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation.

Leiser D, Pochon B, Blank-Liss W, Francica P, Glück AA, Aebersold DM, Zimmer Y, Medová M.

FEBS Lett. 2014 Mar 3;588(5):653-8. doi: 10.1016/j.febslet.2013.12.025. Epub 2014 Jan 17.

18.

The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response-Biological and Clinical Aspects.

Medová M, Aebersold DM, Zimmer Y.

Cancers (Basel). 2013 Dec 19;6(1):1-27. doi: 10.3390/cancers6010001.

19.

The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants.

Medová M, Pochon B, Streit B, Blank-Liss W, Francica P, Stroka D, Keogh A, Aebersold DM, Blaukat A, Bladt F, Zimmer Y.

Mol Cancer Ther. 2013 Nov;12(11):2415-24. doi: 10.1158/1535-7163.MCT-13-0151. Epub 2013 Sep 23.

20.

Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells.

Humbert M, Medová M, Aebersold DM, Blaukat A, Bladt F, Fey MF, Zimmer Y, Tschan MP.

Biochem Biophys Res Commun. 2013 Feb 8;431(2):264-9. doi: 10.1016/j.bbrc.2012.12.120. Epub 2013 Jan 9.

PMID:
23313490
21.

MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest.

Medová M, Aebersold DM, Blank-Liss W, Streit B, Medo M, Aebi S, Zimmer Y.

Genes Cancer. 2010 Oct;1(10):1053-62. doi: 10.1177/1947601910388030.

22.

MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks.

Medová M, Aebersold DM, Zimmer Y.

Int J Cancer. 2012 Feb 1;130(3):728-34. doi: 10.1002/ijc.26058. Epub 2011 May 9.

23.

Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.

Zimmer Y, Vaseva AV, Medová M, Streit B, Blank-Liss W, Greiner RH, Schiering N, Aebersold DM.

Cancer Lett. 2010 Mar 28;289(2):228-36. doi: 10.1016/j.canlet.2009.08.017. Epub 2009 Sep 23.

PMID:
19783361
24.

Hsp90 transcriptionally and post-translationally regulates the expression of NDRG1 and maintains the stability of its modifying kinase GSK3beta.

Banz VM, Medová M, Keogh A, Furer C, Zimmer Y, Candinas D, Stroka D.

Biochim Biophys Acta. 2009 Oct;1793(10):1597-603. doi: 10.1016/j.bbamcr.2009.08.002. Epub 2009 Aug 12.

25.

Coupling of mutated Met variants to DNA repair via Abl and Rad51.

Ganapathipillai SS, Medová M, Aebersold DM, Manley PW, Berthou S, Streit B, Blank-Liss W, Greiner RH, Rothen-Rutishauser B, Zimmer Y.

Cancer Res. 2008 Jul 15;68(14):5769-77. doi: 10.1158/0008-5472.CAN-08-1269.

26.

Influence of KfoG on capsular polysaccharide structure in Escherichia coli K4 strain.

Krahulec J, Krahulcová J, Medová M, Velebny V.

Mol Biotechnol. 2005 Jun;30(2):129-34.

PMID:
15920282
27.

Supplemental Content

Loading ...
Support Center